Codexis to Participate in Upcoming Healthcare Conferences
Rhea-AI Summary
Codexis (NASDAQ: CDXS) has announced its participation in four major healthcare conferences in November 2024. The company will engage in fireside chats at the Stifel Healthcare Conference (New York, November 18), the Jefferies London Healthcare Conference (London, November 19), and the Stephens Annual Investment Conference (Nashville, November 21). Additionally, management will host one-on-one investor meetings at the Craig-Hallum Alpha Select Conference in New York on November 19. Live webcasts of the fireside chats will be available on Codexis's investor relations website, with replays accessible for 90 days post-presentation.
Positive
- None.
Negative
- None.
News Market Reaction – CDXS
In the trading session that priced this news, CDXS gained 9.46%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences.
The Stifel 2024 Healthcare Conference (New York, NY)
- Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat
The Jefferies London Healthcare Conference (London, UK)
- Tuesday, November 19, 2024, at 9:30 am GMT, management will participate in a fireside chat
The 15th Annual Craig-Hallum Alpha Select Conference (New York, NY)
- Tuesday, November 19, 2024, management will host 1x1 investor meetings
The Stephens Annual Investment Conference (Nashville, TN)
- Thursday, November 21, 2024, at 12:00 pm CT, management will participate in a fireside chat
Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay of each fireside chat will be archived for 90 days following the presentation date.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
